Evaluating Vir Biotechnology: Insights From 5 Financial Analysts
Portfolio Pulse from Benzinga Insights
Over the past three months, five analysts have shared their insights on Vir Biotechnology (NASDAQ:VIR), with a mix of bullish and indifferent ratings. The average 12-month price target has significantly increased to $71.4 from a previous $10.00. Analysts from firms like HC Wainwright & Co. and JP Morgan have maintained or raised their ratings, reflecting a positive shift in sentiment. Vir Biotechnology has shown solid revenue growth but faces challenges with its net margin and return on equity.
May 24, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have shown a positive shift in sentiment towards Vir Biotechnology, with the average 12-month price target rising significantly to $71.4. The company has demonstrated solid revenue growth but faces challenges with its net margin and return on equity.
The significant increase in the average price target and the positive shift in analyst sentiment are likely to boost investor confidence in the short term. However, the company's challenges with net margin and return on equity may temper some of the enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100